# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...
- Reuters
Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has r...
Morgan Stanley analyst Terence Flynn reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $1106 price target.
Eli Lilly launches low-dose Zepbound vials for weight loss, offering 2.5 mg and 5 mg options for self-pay patients. These vials...